Seeking Alpha·3d ago
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call TranscriptAcadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
ACADIA's revenue re-accelerated to 22.8% year-over-year growth in 2026Q3 at $342.3M, suggesting Daybue's commercial launch is now contributing meaningfully to top-line expansion, while gross margins near 90% indicate a structurally high-margin product base.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.31+55.6% vs $0.20 | $342M+2.9% vs $333M |
Q3 2026 Aug 4, 2026 | $0.18+164.1% vs $0.07 | $308M+3.8% vs $297M |
Q2 2026 May 6, 2026 | $0.02-50.0% vs $0.04 | $268M-4.3% vs $280M |
Q1 2026 Feb 25, 2026 | $1.60+1067.9% vs $0.14 | $284M-3.0% vs $293M |
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.
ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson's disease psychosis drug NUPLAZID drove growth.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build m.
Benchmark ACAD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ACADIA Pharmaceuticals Inc. (ACAD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $132.37 | $6.81B | -44.14 | 65.55% | -18.18% | -189.73% | — | |
| $3.86 | $1.7B | 6.18 | 31.26% | 15.79% | 14.95% | 2.56% | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $248.35 | $36.69B | 105.48 | 1.39% | 3.38% | 1.86% | — |
ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 23, 2026·SEC
Aug 4, 2026·SEC
Get notified when ACAD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.20B in revenue over the trailing twelve months. Revenue was $1.07B in fiscal year 2025. That is 24749% more than the $4.3M of fiscal year 2000.
ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 14.8% over the trailing twelve months, compared with the twelve months before.
Yes. ACADIA Pharmaceuticals Inc. (ACAD) earned $362.2M in net income over the trailing twelve months (a 30.1% net margin).
ACADIA Pharmaceuticals Inc. (ACAD) had a return on equity (ROE) of 28.0% over the trailing twelve months. That is well above the market's typical 10-15%.
ACADIA Pharmaceuticals Inc. (ACAD) generated $110.8M in free cash flow over the trailing twelve months.
